reading API source threads from 2024 and half of it aged badly
reading API source threads from 2024 and half of it aged badly. It is the sort of thing everyone half-believes and nobody writes down.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
the API source is the question nobody asks and everybody should
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Is the compound still on the shortage list where you are?
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
salt forms are the recurring argument and the answer is boring
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
a 503B has to register and report, so there is a paper trail to ask for
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
potency testing on the finished preparation is the thing to ask for
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
ask which facility, then ask for their testing
compounded is not generic, there is no equivalence claim
if a clinic will not name the facility, that is your answer
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
do not assume the concentration matches the branded product
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
the label on a compounded vial is a legal document, read it
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
a telehealth intake that asks nothing has told you what it is